Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

Offering a rare glimpse inside the hidden world of rejected insurance claims, new data shows a steady uptick among major ...

According to a new report from Big Chalk Analytics, GLP-1 users have cut $6.5 billion from U.S. grocery spend.

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Battered by multiple years of high health care costs, employers are planning to shift more of the expense to workers in 2026, ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

School districts across Minnesota are struggling to contain double-digit health insurance cost increases. Some officials say ...

Ozempic could help with his as a study by Goldman Sachs found that the mass-adoption of GLP-1 series drugs could allow for large-scale economic growth and increase the United States Gross Domestic ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

6 ways employers can lower healthcare costs in 2025 “Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so,” one expert said.

WEIGHT loss jabs could be rolled out by the NHS in pharmacies under plans to make them more widely available and “tackle the obesity epidemic”. Pharmacists could be given the power to ...